2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
33 citations
,
October 2013 in “Journal of The American Academy of Dermatology” Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
9 citations
,
April 2016 in “Australasian journal of dermatology” Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
18 citations
,
September 2016 in “International Journal of Molecular Sciences” Polydeoxyribonucleotide (PDRN) may help lighten skin and treat hyperpigmentation.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
June 2024 in “Journal of medicinal chemistry” A new AI-driven method shows promise for treating hair loss with a peptide-based drug.
3 citations
,
July 2024 in “Cell Proliferation” Blocking TGFβ can help treat fibrotic skin conditions by promoting fat cell formation.
61 citations
,
May 2016 in “Scientific reports” The peptide IMT-P8 can effectively deliver proteins into the skin and cells for potential skin treatments.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
6 citations
,
October 1993 in “Endocrinology” Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
June 2026 in “Eurasian Journal of Medicine” November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
6 citations
,
September 2018 in “International Journal of Molecular Sciences” PRP derivatives are likely safe for therapeutic use without harmful effects.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology” July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
3 citations
,
May 2011 in “Journal of the American Academy of Dermatology” A woman's excessive hair growth around a leg ulcer was linked to a treatment with Prostaglandin E1 ointment.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
May 2024 in “Journal of the Egyptian Womenʼs Dermatologic Society” Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
January 2012 in “Земский врач” Finasteride helps improve treatment for benign prostatic hyperplasia.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
1 citations
,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.
44 citations
,
January 2013 in “BMC Dermatology” TGFβ signaling prevents sebaceous gland cells from producing fats.